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Objective: To estimate the “real-world” effectiveness of commonly used aids to smoking cessation in
England by using longitudinal data.
Patients and Methods: We conducted a prospective cohort study in 1560 adult smokers who participated
in an English national household survey in the period from November 2006 to March 2012, responded to a
6-month follow-up survey, and made at least 1 quit attempt between the 2 measurements. The quitting
method was classiﬁed as follows: (1) prescription medication (nicotine replacement therapy [NRT],
bupropion, or varenicline) in combination with specialist behavioral support delivered by a National Health
Service Stop Smoking Service; (2) prescription medication with brief advice; (3) NRT bought over the
counter; (4) none of these. The primary outcome measure was self-reported abstinence up to the time of the
6-month follow-up survey, adjusted for key potential confounders including cigarette dependence.
Results: Compared with smokers using none of the cessation aids, the adjusted odds of remaining
abstinent up to the time of the 6-month follow-up survey were 2.58 (95% CI, 1.48-4.52) times higher in
users of prescription medication in combination with specialist behavioral support and 1.55 (95% CI,
1.11-2.16) times higher in users of prescription medication with brief advice. The use of NRT bought over
the counter was associated with a lower odds of abstinence (odds ratio, 0.68; 95% CI, 0.49-0.94).
Conclusion: Prescription medication offered with specialist behavioral support and that offered with
minimal behavioral support are successful methods of stopping cigarette smoking in England.ª 2014 Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). n Mayo Clin Proc. 2014;89(10):1360-1367T he evidence for the efﬁcacy of behav-ioral support and several medicationsfor smoking cessation is provided by
multiple randomized controlled trials.1-7 It is
important to supplement the evidence from
these experimental studies with evidence from
observational studies in the “real world.” In a
previous study, we used cross-sectional data
from an English population survey to assess
the effectiveness of medication for smoking
cessation combined with behavioral support in
comparison with unaided quitting.8 A key issue
when using nonrandomized observational data
is to account for potential confounding by indi-
cation; that is, smokers who use one method of
quitting may differ from smokers using another
method of quitting in terms of prognostic fac-
tors. The most important confounder in this re-
gard is cigarette dependence.
In our earlier study,8 we used a validated
measure9 involving ratings of current urgesMayo Clin Proc. n October 2014;89(
n ª 2014 Mayo Foundation for Medical Education and Research. T
nses/by-nc-nd/3.0/).to smoke assessed at the time of the survey
to adjust for potential confounding. In
smokers who were abstinent at the time of
the survey, these measures were assumed to
serve as a valid proxy for urges to smoke at
the time of the quit attempt. This assumption
holds only when different methods of stop-
ping are not differentially linked to lower or
higher levels of urges in abstinent smokers.
We indeed found that urges to smoke in
smokers vs quitters did not differ as a function
of method.8 Still, smokers who used medica-
tion and behavioral support reported higher
levels of urges to smoke than did smokers
who tried to quit unaided. After adjusting for
this confounder, we found that smokers who
use a combination of specialist behavioral sup-
port and medication in their quit attempts had
almost 3 times the odds of success than did
those who used neither medication nor behav-
ioral support. We also found that smokers10):1360-1367 n http://dx.doi.org/10.1016/j.mayocp.2014.07.004
his is an open access article under the CC BY-NC-ND license
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(NRT) over the counter with no behavioral
support had similar odds of success at stop-
ping as did those who stop without any aid.
It is important to conﬁrm these ﬁndings
with longitudinal data that are used to measure
urges to smoke in current smokers at baseline,
before their quit attempt. We conducted a pro-
spective cohort study using data from the
Smoking Toolkit Study to achieve this.
PATIENTS AND METHODS
The Smoking Toolkit Study is an ongoing
research program designed to provide informa-
tion about smoking cessation and factors that
promote or inhibit it at a population level.10,11
Each month a new sample of approximately
1800 people 16 years and older completes a
face-to-face computer-assisted survey, of
whom approximately 450 (25%) are smokers.
The general methodology has been described
in full elsewhere and has been reported to result
in ﬁgures for key variables such as smoking
prevalence that are nationally representative.10
The speciﬁc methodology used for the present
study and described herein was largely based
on our previous study and has been described
in a different article as well.8
Study Population
For the present study, we used aggregated data
from respondents to the baseline survey in the
period fromNovember 2006 (the start of the sur-
vey) to March 2012 (the latest wave of the survey
for which 6-month follow-up data were avail-
able), who smoked cigarettes (including hand-
rolled) or any other combustible tobacco product
(eg, pipe or cigar) daily or occasionally at the time
of the survey. These respondents were asked
whether they were willing to be recontacted. A
follow-up questionnaire was sent to consenting
respondents 6 months after baseline. Participants
were given £5 ($8) remuneration, and 1
reminder letter was sent. Of the 27,219 smokers
at baseline, 5757 (21.2%) were followed up 6
months later. The sample followed up differed
from those not followed up by being more likely
to be female, older, less motivated to stop smok-
ing, and reporting higher strengths of urges to
smoke at baseline. The differences were small
but statistically signiﬁcant (P<.05).
Respondents to the 6-month follow-up were
asked “Have you made a serious attempt to stopMayo Clin Proc. n October 2014;89(10):1360-1367 n http://dx.doi.o
www.mayoclinicproceedings.orgsmoking in the past 12 months? By serious
attempt I mean you decided that you would try
tomake sure younever smokedanother cigarette?
Please include any attempt that you are currently
making.”Those respondents who answered “Yes”
were then asked “How long ago did your quit
attempt start?” The response options to this ques-
tion were as follows: “In the last week”; “More
than a week and up to a month”; “More than 1
month and up to 2 months”; “More than 2
months and up to 3 months”; “More than 3
months and up to 6 months”; “More than 6
months and up to a year”; “Can’t remember.”
We included only those respondents who made
at least 1 quit attempt about 6 months ago.
Measurement of Effect: Use of Smoking
Cessation Treatments
The use of smoking cessation treatments was
assessed only for the most recent quit attempt
and included the following: (1) NRT on prescrip-
tion, bupropion, or varenicline in combination
with specialist behavioral support (ie, one-to-one
or group behavioral support delivered by a Na-
tional Health Service [NHS] Stop Smoking Ser-
vice); (2) NRT on prescription, bupropion, or
vareniclineincombinationwithbriefadvice(deliv-
ered by the prescribing health care professional);
(3) NRT bought over the counter without any
behavioral support; (4) none of these. The behav-
ioral support delivered by an NHS Stop Smoking
Service generally involves at least 6 sessions with
the client (before the quit date, on the quit date it-
self, and 4weekly follow-up sessions), with a total
potential contact time of at least 1.5 hours.12
Measurement of Outcome: Self-Reported
Nonsmoking
Our primary outcome was self-reported
nonsmoking up to the time of the 6-month
follow-up measurement. Respondents were
asked “How long did your most recent serious
quit attempt last before you went back to smok-
ing?” Those responding “I am still not smoking”
were deﬁned as nonsmokers. Previous research
has found that self-reported abstinence in sur-
veys of this kind is not subject to the kind of
biases observed in clinical trials in which there
is social pressure to claim abstinence.13,14
Measurement of Potential Confounders
We measured variables potentially associated
with the use of smoking cessation treatmentsrg/10.1016/j.mayocp.2014.07.004 1361
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These potential confounders were chosen a pri-
ori. The most important factor was cigarette
dependence for which we used 2 questions
assessed at baseline. First, time spent with urges
to smoke was assessed by asking “How much of
the time have you felt the urge to smoke in the
past 24 hours? Not at all (coded 1), a little of
the time (2), some of the time (3), a lot of the
time (4), almost all of the time (5), all of the
time (6).” Second, strength of urges to smoke
was assessed by asking “In general, how strong
have the urges to smoke been?: slight (1), mod-
erate (2), strong (3), very strong (4), extremely
strong (5).” This question was coded “0” for
smokers who responded “Not at all” to the pre-
vious question. These 2 ratings have been found
in this population to be a better measure of
dependence (more closely associated with
relapse after a quit attempt) than other mea-
sures.9 Demographic characteristics we took
into account were age, sex, and social grade
(measured on an ordinal scale: AB¼managerial
and professional occupations; C1 ¼ intermedi-
ate occupations; C2 ¼ small employers and
own account workers; D ¼ lower supervisory
and technical occupations; and E ¼ semi-
routine and routine occupations, never workers,
and long-term unemployed). With regard to the
most recent quit attempt measured at 6-month
follow-up, we asked the time since this quit
attempt was initiated, the number of quit at-
tempts before this attempt that occurred since
baseline, and whether respondents cut down
ﬁrst or stopped abruptly without cutting down.
Data Analyses
Simple associations between potential con-
founders and use of the smoking cessation
treatments were assessed by using analysis of
variance for continuous variables and Pear-
son’s c2 test for categorical variables. The
Games-Howell procedure was used for post
hoc multiple comparisons of the continuous
variables between pairs of treatment groups.
For our primary analysis, we used a multiple
logistic regression model in which we regressed
the outcome measure (self-reported nonsmoking
at 6-month follow-up compared with smoking)
on the effect measure (use of each of the 3 smok-
ing cessation treatments comparedwith no use of
such treatments), adjusted for the above-
mentioned confounders and year of the survey.Mayo Clin Proc. n October 2014;89(In addition to the model from this primary
analysis (“fully adjusted model”), we con-
structed a simplemodel including only the effect
measure (“unadjusted model”) and a model that
included the effect measure, year of the survey,
and all confounders except for the 2 measures
of tobacco dependence (“partially adjusted
model”) to show the extent of confounding ef-
fects of tobacco dependence.
In a sensitivity analysis, we excluded re-
spondents who had used telephone counseling
for smoking cessation during their most recent
quit attempt; very few smokers in England use
this form of treatment, and so it is not possible
to assess its association with abstinence. In the
primary analysis, these smokers were conserva-
tively counted in the “no-treatment” group un-
less they had also used medication, whereas in
the sensitivity analysis, they were excluded
from the analysis.
All analyses were performed with complete
cases. Respondents with missing data on 1 or
more of the confounding variables were
excluded (0.3% of the eligible sample).
RESULTS
The study population consisted of 1560 respon-
dents with complete baseline and 6-month
follow-up data who made at least 1 quit attempt
between the 2 time points. Demographic and
smoking-related characteristics are summarized
in Table 1. The percentage of usage of smoking
cessation treatments during the last quit attempt
was 4.8% (n¼75) for prescription medication
combined with specialist behavioral support,
20.8% (n¼324) for prescription medication
combined with brief advice, 29.9% (n¼467)
for NRT bought over the counter, and 44.5%
(n¼694) for using none of these treatments. A
total of 399 respondents (25.6%) had used
some form of prescription medication during
their most recent quit attempt; most of them
had used NRT on prescription (56.9%,
n¼227), followed by varenicline (35.1%,
n¼140) and bupropion (6.0%, n¼24). The
remaining 2.0% (n¼8) of respondents had
used some combination of these medications.
A total of 1201 respondents (77.0%)
smoked, and 359 (23.0%) reported not smoking
at the 6-month follow-up. The unadjusted absti-
nence rates were 38.7% (n¼29) for users of
medication on prescription combined with
specialist behavioral support, 27.8% (n¼90) for
10):1360-1367 n http://dx.doi.org/10.1016/j.mayocp.2014.07.004
www.mayoclinicproceedings.org
TABLE 1. Sample Characteristics (N¼1560)a
Nonsmoker at follow-up 23.0 (359)
Age at baseline 46.515.7
Female sex 55.8 (871)
Social grade
AB 11.0 (171)
C1 20.9 (326)
C2 22.0 (343)
D 17.5 (273)
E 28.7 (447)
Time spent with urges to smoke at baselineb 3.21.2
Strength of urges to smoke at baselinec 2.21.0
Time since last quit attempt started at follow-up
1 wk 10.5 (164)
2-4 wk 21.1 (329)
5-8 wk 21.0 (327)
9-12 wk 19.8 (309)
13-26 wk 27.6 (431)
Number of quit attempts before the most recent one and up to 6 mo at
follow-up
0 69.2 (1079)
1 22.5 (351)
2 8.3 (130)
Stopped abruptly during last quit attempt at follow-up (vs cut down ﬁrst) 47.9 (747)
Use of smoking cessation treatments during last quit attempt at follow-up
Medication on prescription combined with specialist behavioral
supportd 4.8 (75)
Medication on prescription combined with brief adviced 20.8 (324)
NRT bought over the counter 29.9 (467)
None of the above 44.5 (694)
aValues are expressed as mean  SD or as No. (percentage).
bTime spent with urges to smoke: 1 (not at all) to 6 (all the time).
cStrength of urges to smoke: 0 (no urges) to 5 (extremely strong urges).
dMedication on prescription included nicotine replacement therapy (NRT), varenicline, or
bupropion.
REAL-WORLD EFFECTIVENESS OF SMOKING CESSATION TREATMENTSusers of prescription medication combined with
brief advice, 15.4% (n¼72) for users of NRT
bought over the counter, and 24.2% (n¼168)
for those using none of these treatments.
The use of treatments was associated with
age, time since last quit attempt started, num-
ber of quit attempts before the most recent
one, the 2 measures of dependence (time
spent with and strength of urges to smoke),
and social grade (Table 2). The post hoc com-
parisons established that users of medication
(on prescription or over the counter) reported
higher levels of dependence than did respon-
dents who had tried to quit unaided.
Table 3 reveals that the fully adjusted odds
of nonsmoking in users of prescription medica-
tion in combination with specialist behavioral
support were 2.58 times higher (95% CI,
1.48-4.52) than in the no-treatment group.
The odds were 1.67 times higher (95% CI,
0.94-2.98) than in the group that used pre-
scription medication combined with brief
advice, but this difference was not statistically
signiﬁcant (ﬁgures not shown in the table). In
the latter group, the odds were 1.55 times
higher (95% CI, 1.11-2.16) than in the no-
treatment group. The use of NRT bought over
the counter was associated with lower odds of
abstinence (odds ratio, 0.68; 95% CI, 0.49-
0.94). In the partially adjusted model, the
odds ratios for the 2 groups that used prescrip-
tion medication were slightly lower than in the
fully adjusted model, whereas the odds ratio for
the group that used NRT bought over the
counter was slightly more extreme.
A total of 24 respondents (1.5%) reported
having used telephone counseling during their
most recent quit attempt. Excluding these re-
spondents from the primary analysis changed
the odds ratios of the fully adjusted model
only minimally.
DISCUSSION
This prospective cohort study found that the
use of prescription medication in combination
with specialist behavioral support provided by
an NHS Stop Smoking Service was associated
with the highest success of attempts to quit
smoking. The use of prescription medication
with limited behavioral support by the pre-
scribing health care professional was also asso-
ciated with higher success than was unaided
quitting, whereas the use of NRT boughtMayo Clin Proc. n October 2014;89(10):1360-1367 n http://dx.doi.o
www.mayoclinicproceedings.orgover the counter was associated with lower
success.
Comparison With Findings From
Randomized Controlled Trials
Our estimated effectiveness of adding specialist
behavioral support provided by an NHS Stop
Smoking Service to prescription medication
(adjusted odds ratio, 1.67) is similar to that
from a meta-analysis performed for the US
guidelines.15 Also, our estimated effectiveness
of prescription medication combined with
limited behavioral support by the prescribing
health care professional compared with unaided
quitting (adjusted odds ratio, 1.55) is similar to
that frommeta-analyses of randomized placebo-
controlled trials.4-6 However, our adjusted odds
ratio of 0.68 in users of NRT bought over the
counter compared with that in those who usedrg/10.1016/j.mayocp.2014.07.004 1363
TABLE 2. Associations Between Characteristics of the Sample and Use of Smoking Cessation Treatmentsa
Variable
Medication on prescription
combined with specialist
behavioral supportb
(n¼75)
Medication on
prescription combined
with brief adviceb
(n¼324)
NRT bought
over the counter
(n¼467)
None of
the others
(n¼694) P
Age at baseline 52.013.01 48.613.82 46.615.41 44.916.81,2 <.001
Female sex 50.0 (31) 56.4 (167) 57.1 (306) 54.1 (398) .22
Social grade
AB 16.1 (10) 8.1 (24) 11.0 (59) 11.7 (86) .007
C1 14.5 (9) 22.6 (67) 20.0 (107) 20.8 (153)
C2 30.6 (19) 16.9 (50) 22.2 (119) 23.1 (170)
D 4.8 (3) 20.9 (62) 15.7 (84) 18.2 (134)
E 33.9 (21) 31.4 (93) 31.2 (167) 26.1 (192)
Time spent with urges to smoke at baselinec 3.71.23 3.51.24 3.31.25 2.91.13,4,5 <.001
Strength of urges to smoke at baselined 2.51.06 2.41.17 2.31.08 2.01.06,7,8 <.001
Time since quit attempt started at follow-up <.001
1 wk 4.8 (3) 8.8 (26) 9.1 (49) 12.8 (94)
2-4 wk 25.8 (16) 11.5 (34) 23.3 (125) 22.4 (165)
5-8 wk 16.1 (10) 20.9 (62) 22.0 (118) 20.3 (149)
9-12 wk 24.2 (15) 26.0 (77) 17.7 (95) 18.1 (133)
13-26 wk 29.0 (18) 32.8 (97) 27.8 (149) 26.4 (194)
Number of quit attempts before the most recent
one and up to 6 mo at follow-up .002
0 75.8 (47) 77.4 (229) 67.2 (360) 67.6 (497)
1 14.5 (9) 17.2 (51) 23.9 (128) 23.1 (170)
2 9.7 (6) 5.4 (16) 9.0 (48) 9.3 (68)
Stopped abruptly during last quit attempt at
follow-up (vs cut down ﬁrst)
48.4 (30) 44.9 (133) 45.7 (245) 50.1 (368)
.14
aValues are expressed as mean  SD or as No. (percentage).
bMedication on prescription included nicotine replacement therapy (NRT), varenicline, or bupropion.
cTime spent with urges to smoke: 1 (not at all) to 6 (all the time).
dStrength of urges to smoke: 0 (no urges) to 5 (extremely strong urges).
Superscript numbers 1-8 indicate statistically signiﬁcant (P<.05) differences between groups with the same letter according to the post hoc analyses.
TABLE 3. Unadjusted and
Sm
Medication on prescription
Medication on prescription
NRT bought over the coun
None of the above (referen
aPartially adjusted model was ad
cutting down, and year of the
bFully adjusted model was adjus
cMedication on prescription inc
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1364neither medication nor behavioral support
(indicating a reduced likelihood of quitting in
users of NRT bought over the counter) conﬂicts
with a meta-analysis that reported a pooled odds
ratio of 2.5 for active NRT bought over the
counter vs placebo.16 This discrepancy seems
unlikely to relate to the difference in studyAdjusted Odds of Self-Reported Nonsmoking at 6-mo Foll
oking cessation treatment Unadjuste
combined with specialist behavioral support (n¼62)c 1.98 (1.2
combined with brief advice (n¼296)c 1.20 (0.8
ter (n¼536) 0.57 (0.4
ce) (n¼735) 1
justed for age, sex, social grade, time since last quit attempt started, numbe
survey.
ted for the variables from the partially adjusted model and for time spen
luded nicotine replacement therapy (NRT), varenicline, or bupropion.
Mayo Clin Proc. n October 2014;89(designs or unmeasured confounding because
our prospective cohort design yielded similar re-
sults as experimental designs with regard to the
use of prescription medication and behavioral
support, as noted above. Therefore, the most
likely explanation for the low success rate of
NRT bought over the counter in our study isow-Up Stratiﬁed by the Method of Quitting
Odds ratio (95% CI)
d model Partially adjusted modela Fully adjusted modelb
0-3.24) 2.27 (1.32-3.92) 2.58 (1.48-4.52)
9-1.62) 1.38 (1.00-1.91) 1.55 (1.11-2.16)
2-0.78) 0.62 (0.45-0.85) 0.68 (0.49-0.94)
1 1
r of quit attempts before the one in question, stopping abruptly vs
t with urges to smoke and strength of urges to smoke.
10):1360-1367 n http://dx.doi.org/10.1016/j.mayocp.2014.07.004
www.mayoclinicproceedings.org
REAL-WORLD EFFECTIVENESS OF SMOKING CESSATION TREATMENTSinappropriate usage and low adherence in the
real world.17,18 Experimental studies cannot
mimic the usual environment in which over-the-
counter medication is used because trial participants
are instructed on how to use the medication, and
their adherence to this medication is monitored
and promoted during the trial. For example, the au-
thors from the largest placebo controlled trial ofNRT
bought over the counter, which contributed to the
above-mentioned meta-analysis, acknowledged
that “complete reproducibility of the over-the-
counter setting was impossible.”19 In that trial, par-
ticipants were asked to set a quit date within 7
days; they were given instructions on how to use
the medication, the ﬁrst use was under supervision,
adverse events were monitored, and adherence was
maintained during several site visits.19 This is a
different situation from the real-world setting of
our study in which smokers use the medication in
an uncontrolled yet more realistic fashion.
Comparison With Findings From
Observational Studies
One of the aims of this prospective cohort
study was to conﬁrm the ﬁndings from our
earlier cross-sectional study on the real-world
effectiveness of smoking cessation treatments.8
The ﬁndings from the present study regarding
prescription medication largely conﬁrm those
from our earlier study, even though the 2 effect
estimates for prescription medication with or
without specialist behavioral support were
closer to 1 in this study, suggesting that resid-
ual confounding played a greater role in our
previous study. Although NRT bought over
the counter was equally associated with the
success of quitting than not using treatment
in our earlier study (adjusted odds ratio, 0.96;
95% CI, 0.81-1.13),8 NRT bought over the
counter was associated with a signiﬁcant reduc-
tion in success in our present study (adjusted
odds ratio, 0.68; 95% CI, 0.49-0.94).
Our ﬁnding of a positive association be-
tween the use of prescription medication and
the success of attempts to quit smoking is
largely consistent with previous prospective
cohort studies.20-25 For example, a study using
data from 12,156 treatment episodes routinely
recorded by 31 NHS Stop Smoking Services in
England found that specialist behavioral sup-
port combined with dual NRT (but not single
NRT), varenicline, or bupropion was associated
with a higher rate of success of quit attemptsMayo Clin Proc. n October 2014;89(10):1360-1367 n http://dx.doi.o
www.mayoclinicproceedings.orgthan was behavioral support without medica-
tion.20 A study in 7436 smokers taking part
in the International Tobacco Control Four
Country Study reported higher success rates
in smokers trying to quit who used NRT, vare-
nicline, or bupropion than in smokers trying to
quit without medication, although the effect es-
timates were much higher than in our study.21
Another international study in more than 1089
smokers from 5 different countries reported a
higher success rate in smokers who used NRT
than in smokers who did not use NRT, again
with higher effect estimates than in our study.22
Study Limitations
This study has several limitations. First, the
response to our 6-month follow-up was only
21% and the response also differed slightly by
demographic and smoking characteristics. A
higher responsewould have resulted in increased
statistical power, but our sample was large
enough to statistically detect the differences in
success rates between the treatment groups.
We have no reason to assume that the somewhat
differential nonresponse biased our estimates for
the relative effectiveness of the treatments, but it
may have reduced the generalizability of our
ﬁndings to a small extent. Second, nonrandom-
ized studies are generally vulnerable to con-
founding. We reduced this risk further than
did many previous studies by adjusting for to-
bacco dependencedmeasured before a quit
attempt was initiateddand several other poten-
tial confounders. However, residual confound-
ing may have occurred because not all factors
associated with self-selection of treatment, such
as comorbidity26 or psychological distress,27
were measured in our survey. Third, our self-
reported outcome measure of abstinence from
smoking was not biochemically validated. In
observational studies such as ours, however, it
is unlikely that misreporting of abstinence is
associated with the type of treatment respon-
dents used during the last quit attempt they
recall.13,14 Fourth, we did not have data on
actual use of, and adherence to, the medication
and the behavioral support. We have no reason
to assume that the report of various treatments
was dependent on the respondents’ smoking sta-
tus at the 6-month follow-up measurement. If
bias occurred, this would have led to an underes-
timation of the effectiveness of prescription
medication and specialist behavioral supportrg/10.1016/j.mayocp.2014.07.004 1365
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1366because unaided quit attempts that fail are more
likely to be forgotten.28 An improved real-world
design that would reduce the risk of confounding
and the reliance on recall data may involve base-
line characteristics to be collected ﬁrst and then
recent treatment assessed at a second time point
before assessing smoking status at the ﬁnal
follow-up. Finally, our sample size was too small
for comparing the differential effectiveness of
different prescription medications.
Strengths
As far as we are aware, our study is the ﬁrst
prospective cohort study comparing prescrip-
tion medication when offered with specialist
behavioral support with prescription medica-
tion offered without such support. A major
strength of our study is the use of a represen-
tative sample of the English population that
was sufﬁciently large to detect an effect of
specialist behavioral support despite its low
prevalence. We used aggregated data from
monthly surveys over a period of more than
5 years and therefore minimized potential
bias from the rate of quit attempts depending
on the time of the year.
CONCLUSION
The use of prescription medication with
specialist behavioral support delivered by an
NHS Stop Smoking Service or with minimal
behavioral support is associated with improved
outcomes compared with unaided quitting.
Thus,more smokers should be guided into these
forms of treatment because currently only 1 of 4
smokers attempting to quit use them. The most
frequently used form of treatment, NRT bought
over the counter, appears to be associated with
reduced success rates. More research is urgently
needed on the effectiveness of NRT bought
over the counter in the real world.Abbreviations and Acronyms: NHS = National Health
Service; NRT = nicotine replacement therapy
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